Innovating Cell Therapy
With our ACUA technology platform, we discover and develop off-the-shelf allogeneic cell therapies for cancer patients from healthy donor hematopoietic stem cells. Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cells. and gamma delta T cells. Our research and development efforts are focused on engineered allogeneic cell therapies with a scalable technology platform to increase therapeutic options and availability for patients.
MEDIA & PRESS UPDATES
We’re a growing early-stage biotechnology company. We're looking for talented people who are passionate about innovating new medicines at the cutting-edge of science.
See our job listings at:
Or visit our LinkedIn company page:
6160 Bristol Parkway #300 Culver City, CA 90230